Dietary phosphate supplement does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia
© The Author(s). 2016
Received: 24 May 2016
Accepted: 27 September 2016
Published: 26 October 2016
Mutations in the human progressive ankylosis gene (ANKH; Mus musculus ortholog Ank) have been identified as cause for craniometaphyseal dysplasia (CMD), characterized by progressive thickening of craniofacial bones and flared metaphyses of long bones. We previously reported a knock-in (KI) mouse model (Ank KI/KI) for CMD and showed transiently lower serum phosphate (Pi) as well as significantly higher mRNA levels of fibroblast growth factor 23 (Fgf23) in Ank KI/KI mice. FGF23 is secreted by bone and acts in kidney to promote Pi wasting which leads to lower serum Pi levels. Here, we examined whether increasing the Pi level can partially rescue the CMD-like skeletal phenotype by feeding Ank +/+ and Ank KI/KI mice with high Pi (1.7 %) diet from birth for 6 weeks. We studied the Pi metabolism in Ank KI/KI mice and CMD patients by examining the Pi regulators FGF23 and parathyroid hormone (PTH).
High Pi diet did not correct CMD-like features, including massive jawbone, increased endosteal and periosteal perimeters and extensive trabeculation of femurs in Ank KI/KI mice shown by computed microtomography (μCT). This unexpected negative result is, however, consistent with normal serum/plasma levels of the intact/active form of FGF23 and PTH in Ank KI/KI mice and in CMD patients. In addition, FGF23 protein expression was unexpectedly normal in Ank KI/KI femoral cortical bone as shown by immunohistochemistry despite increased mRNA levels for Fgf23. Renal expression of genes involved in the FGF23 bone-kidney axis, including mFgfr1, mKlotho, mNpt2a, mCyp24a1 and m1αOHase, were comparable between Ank +/+ and Ank KI/KI mice as shown by quantitative real-time PCR. Different from normal FGF23 and PTH, serum 25-hydroxyvitamin D was significantly lower in Ank KI/KI mice and vitamin D insufficiency was found in four out of seven CMD patients.
Our data suggests that FGF23 signaling and Pi metabolism are not significantly affected in CMD and transiently low Pi level is not a major contributor to CMD.
KeywordsCraniometaphyseal dysplasia ANKH FGF23 Phosphate diet
Craniometaphyseal dysplasia (CMD), a rare genetic bone disorder, is characterized by progressive thickening of craniofacial bones and flared metaphyses of long bones . CMD patients frequently suffer from hearing loss, visual impairment, facial paralysis and severe headaches due to consequences from neuronal compression as a result of hyperostosis of craniofacial bones [2, 3]. Treatment for CMD is currently limited to risky surgery to relieve neurologic symptoms, mainly because its pathogenesis is not well understood. A major hurdle for studying CMD and many other rare genetic bone disorders is the unavailability of specimens for research. We previously generated a knock-in (KI) mouse model by introducing a Phe377del mutation in Ank (progressive ankylosis gene), one of the most commonly identified mutations in CMD patients . Homozygous Ank KI/KI mice replicate many features of CMD patients, including hyperostostic craniofacial bones, massive jaw bones, flared metaphyses with extensive trabeculation and fusion of middle ear bones . Ank KI/KI mice differ from CMD patients in joint stiffness of elbows, knees, paws and vertebrae. This difference could be due to the autosomal dominant nature of ANK mutations in CMD patients and the mice we study are homozygous for the mutation. Heterozygous Ank +/KI mice do not have joint stiffness and only develop an intermediate skeletal CMD phenotype as they age . Interestingly, Ank KI/KI mice present with significantly lower serum phosphate (Pi) levels at the age of 6 weeks but recover with age. Ank KI/KI mice display remarkably increased fibroblast growth factor 23 (Fgf23) mRNA expression in bones and develop hypomineralization of bones .
FGF23, a phosphaturic factor, is secreted by bone and acts in kidney to promote Pi wasting. It decreases 1,25-(OH)2D3 by reducing expression of 1-α hydroxylase, Npt2a/2c (Na-Pi transporter) and by increasing the 24-hydroxylase level upon binding to its receptor Fgfr1 and co-receptor Klotho [6, 7]. Overexpression of FGF23 in mice leads to hypophosphatemia, hypomineralization, rickets and decreased 1,25-(OH)2D3, whereas ablation of FGF23 in mice leads to hyperphosphatemia, soft tissue calcification and increased 1,25-(OH)2D3 [8, 9]. Although much research has been done on FGF23, its role in the pathogenesis of CMD has never been addressed.
Mutations for the autosomal dominant form of CMD have been identified in the human progressive ankylosis gene (ANKH, encoding ANK), which is a known pyrophosphate (PPi) transporter [10, 11]. ANK controls Pi/PPi homeostasis together with plasma cell membrane glycoprotein (PC-1, encoded by ectonucleotide pyrophosphatase Enpp1), which generates PPi from nucleoside triphosphates (ATP) and tissue nonspecific alkaline phosphatase (TNAP, encoded by Tnap), which hydrolyzes extracellular PPi (ePPi) to generate Pi. The physiological concentration of ePPi in bone acts as a potent inhibitor of hydroxyapatite mineralization while supersaturation of ePPi leads to calcium pyrophosphate dehydrate (CPPD) crystal formation. Ank knock-out (Ank KO/KO) mice exhibit joint stiffness due to the lack of PPi transporter, which results in excessive hydroxyapatite deposition in joints . Pi is a major component of hydroxyapatite and promotes mineralization. A tightly controlled balance between extracellular Pi and PPi is required to maintain normal skeletal mineralization. CMD mutations in ANK result in reduced PPi-transport activity when overexpressed in oocytes . How changes of Pi levels affect skeletal phenotypes in CMD and whether Pi can be used to treat CMD in mice or human have not been investigated.
The only source of Pi is from diet and Pi homeostasis is mainly regulated by three organs, parathyroid gland, kidney and bone, which produce parathyroid hormone (PTH), 1,25-(OH)2D3 (calcitriol, vitamin D) and FGF23, respectively. These three regulatory loops interact with one another. PTH stimulates Pi excretion and vitamin D production in kidney and stimulates FGF23 production in bone. PTH increases Fgf23 expression in calvariae/femurs and serum FGF23 levels likely via activation of osteoblasts . Low Pi and vitamin D in turn can inhibit PTH production. Vitamin D also increases Pi reabsorption and thus modulates bone formation and resorption. FGF23 increases Pi wasting and decreases vitamin D production. Vitamin D increases FGF23 production in bone and FGF23 acts as a counter-regulatory hormone to prevent the hyperphosphatemic effects of excess vitamin D [15, 16].
In order to study the involvement of Pi metabolism in CMD, we examined the levels of FGF23, PTH and 1,25-(OH)2D3 in a knock-in mouse model for CMD and in plasma collected from seven CMD patients. We fed mice with high Pi diet to evaluate whether the transiently lower serum Pi contributes to skeletal abnormalities in CMD and whether supplying increased dietary Pi ameliorates skeletal phenotypes of Ank KI/KI mice. Our results showed that Pi regulators were only mildly changed in CMD and high Pi diet did not correct hyperostosis in Ank KI/KI mice.
A mouse model with a deletion of TTC1130–1132 (phenylalanine 377) in exon 9 of Ank has been previously shown to replicate many features of human CMD . Mice were bred from 129/Sv into a C57Bl/J6 background (N5) for skeletal analysis. High phosphate diet (1.5 %) (Harlan Teklad) was provided to mothers with litters after birth. Offspring were continuously fed with the modified diet for another 3 weeks after weaning. Thus, mice were fed with high Pi diet for a total of 6 weeks. Normal mouse chow contained 0.7 % phosphorus. The animal protocol (100782–1116) was approved by the Institutional Animal Care and Use Committee (IACUC) of University of Connecticut Health and all work was performed in an AAALAC accredited facility.
Blood of mice was obtained from the submandibular vein (Goldenrod animal lancet; Braintree Scientific) and collected in Microtainer tubes (Becton Dickinson). Fasting mouse sera were prepared from 3-, 10- and 16-week-old male Ank +/+ and Ank KI/KI mice. Fasting human plasma was obtained from seven CMD patients. Research involving human subjects has been approved by the University of Connecticut Health Institutional Review Board (IRB number: 03-008-1) and written informed consent has been obtained from all participants. Concentrations of mouse intact FGF23 (mouse intact FGF23 ELISA kit; Kainos), mouse C-terminal FGF23 form (mouse FGF23 C-terminal ELISA kit; Immutopics), human intact FGF23 and C-terminal FGF23 form (human FGF23 intact ELISA kit, human FGF23 C-terminal ELISA kit; Immutopics), mouse/human 25-hydroxy vitamin D (25-hydroxy vitamin D kit; IDS), mouse and human intact PTH (mouse and human intact PTH ELISA kit; Immutopics) were determined according to manufacturers’ instructions.
Femurs from 16-week-old male Ank +/+ and Ank KI/KI mice were dissected, fixed in 4 % paraformaldehyde, decalcified in 14 % ethylenediaminetetraacetic acid, processed and embedded in paraffin. Series of 5 μm sections were collected using the central vein as marker. Briefly, the sections were pretreated with peroxidase blocking reagent, blocked with 1 % bovine serum albumin and 5 % normal goat serum for 30 min at room temperature and incubated with primary FGF23 antibody (1:50 dilution; MAB26291; R&D Systems). After washing, the sections were incubated with anti-rat HRP substrate and DAB (Vector Labs) and counterstained with methyl green. Isotype rat IgG2a control (R&D Systems) and femoral sections from FGF23 null mice (a kind gift of Dr. Beate Lanske) were used as negative controls for antibody specificity. The percentage of FGF23-positive cells over total osteocytes in cortical bones (from just below the growth plate to mid femurs) was determined.
Quantitative real-time PCR (qPCR)
Amplification primers for qPCR
5'- GGTCACACGGTTGGGTTTGTCCTTATCCAG -3'
5′- CTGGCTAAGGTTCAAGTACGGAGACCTCCC −3′
5'- GGAGCTGAGCGATCACTAAGTGAATACGCA -3'
5'- CTCATTGTGGGTGCCCAACATGATG -3'
5'- ACCATGTGTCTCCCACGGACTGGAAG -3'
5'- CTGCCCCATTGACAAAAGGC -3'
5'- CTCACCGTCGGTCATCAGC -3'
5'- TCAGATGTTTGCCTTTGCCC -3'
5'- TGGTTCCTCATCGCAGCTTC -3'
Mandibles and femurs from mice fed with normal and high Pi diet for 6 weeks after birth were evaluated by μCT at the μCT Core Facility at UConn Health (mCT20; ScanCo Medical). For mandibles, the total volume (TV) and bone volume (BV) were measured. For femurs, the metaphyseal trabeculation and cortical bone parameters were measured as described previously .
Statistical analysis was performed by Student’s t-test or analysis of variance (ANOVA) using Prism 5 software (GraphPad Software). Data was presented as mean ± standard deviation and statistically significant difference was considered for p < 0.05.
Effects of high Pi diet on skeleton of Ank KI/KI mice
We previously showed that serum Pi levels were decreased in 6-week-old Ank KI/KI mice fed with regular diet (Ank +/+ = 6.622 ± 1.102 mg/dl, n = 10; Ank KI/KI = 5.494 ± 0.893 mg/dl, n = 11; p < 0.05) and were normal in 10-week-old Ank KI/KI mice . To examine whether dietary Pi can rescue the CMD-like skeletal phenotype, we fed high Pi diet (1.5 %) to Ank +/+ and Ank KI/KI mice continuously for 6 weeks after birth. Serum Pi levels in mice fed with high Pi diet for 6 weeks did increase (Ank +/+ = 7.554 ± 0.745 mg/dl, n = 9; Ank KI/KI = 6.799 ± 0.771 mg/dl, n = 7) but no significant difference between Ank +/+ and Ank KI/KI mice was detected.
μCT analysis of 6-week-old male Ank +/+ and Ank KI/KI mice fed with normal and high Pi diet
Ank +/+(n = 4)
Ank KI/KI (n = 5)
Ank +/+(n = 7)
Ank KI/KI (n = 8)
Total volume (mm3)
0.28 ± 0.01
0.42 ± 0.02c
0.31 ± 0.01a
0.51 ± 0.04b, c
Bone volume (mm3)
0.18 ± 0.02
0.31 ± 0.03c
0.23 ± 0.001a
0.44 ± 0.04b, c
66.5 ± 0.2
77.4 ± 2.2c
74 ± 2.3a
86 ± 0.01b, c
Femur trabecular bone (metaphyses)
5.9 ± 0.4
9.1 ± 0.4c
9.7 ± 3.1
9.9 ± 2.3
Trabecular number (N/mm)
4 ± 0.01
5.3 ± 0.12c
5.27 ± 0.81a
5.66 ± 0.48
Trabecular thickness (μm)
34 ± 2.4
37.6 ± 0.86c
36.2 ± 2.5
36.6 ± 2.2
Trabecular Spacing (μm)
248.53 ± 19.49
186.9 ± 5.62c
193.19 ± 32.10a
173.35 ± 15.68
Femur cortical bone (diaphyses)
Subperiosteal area (mm2)
1.64 ± 0.11
2.26 ± 0.22c
1.20 ± 0.32a
1.7 ± 0.10b, c
Subendosteal area (mm2)
1.05 ± 0.06
1.46 ± 0.16c
0.88 ± 0.14
1.18 ± 0.09c
Cortical porosity (%)
0.4 ± 0.2
1.95 ± 0.01c
0.4 ± 0.23
1.16 ± 0.01c
Tissue density (mg/cm3 HA)
1135.0 ± 30.9
1125.0 ± 13.5c
1141.6 ± 11.1
1106.4 ± 16.1c
FGF23 expression in Ank KI/KI mice
Intact FGF23 protein will become inactive after being cleaved. To examine whether the discrepancy between mRNA and protein levels of FGF23 in Ank KI/KI mice is due to increased proteolytic processing of FGF23, we investigated FGF23 serum levels in male mice at ages 3, 10 and 16 weeks by ELISA using antibodies recognizing the full-length FGF23, which is the biologically active form, or antibodies recognizing both full-length and C-terminal fragments of FGF23. Cleaved FGF23 is the inactive form. Ank KI/KI mice showed a trend but no statistical significance in the increase of intact FGF23 but a significant increase in the inactive C-terminal fragment of FGF23 suggesting that more FGF23 is processed in Ank KI/KI mice. This significant increase is only observed in 16-week-old Ank KI/KI mice but not at ages of 3 or 10 weeks (Fig. 2b).
Galnt3, a GalNac-transferase, prevents the proteolytic processing of FGF23 by mediating the glycosylation of a furin-like convertase recognition sequence in FGF23 . To examine whether increased serum C-terminal FGF23 in Ank KI/KI mice is due to changes in Galnt3 gene expression, we examined Galnt3 mRNA expression by qPCR and found comparable levels of Galnt3 between Ank +/+ and Ank KI/KI mice (Fig. 2c). This finding indicates that the increased C-terminal form of FGF23 in Ank KI/KI mice is likely Galnt3-independent. The activity of GALNT3 protein or other mechanisms regulating post-translational modification of FGF23 will need further investigation.
Renal expression of genes involved in FGF23 bone-kidney axis
Body weight, kidney weight (sum of right and left kidneys) and the ratio of kidney to body weight in Ank +/+ and Ank KI/KI mice
BW 6 weeks
22.83 ± 1.91 (n = 7)
20.83 ± 2.27 (n = 8)
BW 10 weeks
27.35 ± 2.94 (n = 12)
23.46 ± 1.57a (n = 10)
BW 20 weeks
38.37.2 ± 6.3 (n = 10)
20.54 ± 2.96b (n = 6)
KW 6 weeks
359.5 ± 26.8
334.1 ± 53.2
KW 10 weeks
336.3 ± 64.0
297.9 ± 72.7
KW 20 weeks
455.0 ± 68.9
329.5 ± 66.5b
KW/BW 6 weeks
15.75 ± 0.15
16.08 ± 2.17
KW/BW 10 weeks
12.45 ± 2.60
12.69 ± 3.06
KW/BW 20 weeks
12.01 ± 1.54
15.99 ± 2.13b
PTH and 25(OH) vitamin D in mouse serum
Parathyroid hormone (PTH), 1,25-(OH)2D3 (calcitriol) and FGF23 interact to maintain Pi homeostasis. We previously reported lower Pi serum levels and normal PTH in Ank KI/KI mice at the age of 6 weeks. However, the lower Pi serum level was within normal range as mice aged to 10 weeks and older . Because we found an increasing tendency of the active form of FGF23 in Ank KI/KI mice as they aged, we decided to measure serum PTH and 25-hydroxy vitamin D at ages of 10 weeks and 16 weeks. 25-hydroxy vitamin D (25OHD) is a pre-hormone that is converted into 1,25-(OH)2D3 in the kidneys and is considered the best indicator of vitamin D status. Serum PTH levels were comparable between Ank +/+ and Ank KI/KI mice (10 weeks PTH, Ank +/+:Ank KI/KI = 238.25 ± 135.66 (pg/ml) (n = 19) : 217.83 ± 99.01(pg/ml) (n = 16); 16 weeks PTH, Ank +/+:Ank KI/KI = 222.13 ± 66.8 (pg/ml) (n = 5) : 242.98 ± 59.8 (pg/ml) (n = 5)). 25OHD was significantly reduced at the age of 10 weeks (Ank +/+:Ank KI/KI = 41.5 ± 6.61 (ng/ml) (n = 13) : 32.01 ± 2.96 (ng/ml) (n = 12), p < 0.05) but not at 16 weeks (Ank +/+: Ank KI/KI = 41.21 ± 7.42 (ng/ml) (n = 9) : 36.83 ± 5.79 (ng/ml) (n = 12), p = 0.16).
Biochemical analysis of plasma from CMD patients
Biochemical analysis of plasma from CMD patients
C331 → R
Pi metabolism plays an important role in the regulation of skeletogenesis . Serum Pi levels in CMD patients have been reported as transiently lower or normal [19–21]. Consistently, we observed lower serum Pi levels in Ank KI/KI mice at the age of 6 weeks but serum Pi levels were normal in 10-week-old Ank KI/KI mice . Interestingly, mild hypophosphatemia has also been associated with patients expressing a homozygous ANKH missense mutation (Leu244Ser) and presenting mental retardation, hearing loss, ankylosis, periarticular ligament ossification, enthesopathy, and dentinogenesis imperfecta .
In order to study whether Pi metabolism is abnormal in mice and patients with CMD and whether dietary Pi affects the bone phenotype in the CMD mouse model we utilized high Pi diet in mice to examine the effects of Pi on the bone phenotype. We compared Ank +/+ and Ank KI/KI littermates fed with normal mouse chow and high Pi diet. We detected increased serum Pi levels after feeding mice with high Pi diet for 6 weeks. As expected, high Pi diet increases the bone volume in general because Pi is required for hydroxyapatite (calcium phosphate) formation. Pi can also affect osteoclast activity although its effects remain controversial. It has been shown that high Pi decreased osteoclastogenesis in vitro . On the other hand, high Pi diet has been shown to increase osteoclast numbers in the Hyp mice . Our μCT data showed that phenotypic differences between Ank +/+ and Ank KI/KI mice, including the club-shaped femurs, increased cortical porosity and hyperostosis of mandibles in Ank KI/KI mice, did not change with high Pi diet. We therefore, did not further perform static or dynamic histomorphometry with these bones. This data indicates that dietary Pi supplement is not efficient in correcting the CMD phenotype and may be counterproductive.
We examined FGF23 and the FGF23-mediated bone-kidney axis because we previously found significantly increased Fgf23 mRNA levels in calvarial and femoral bones of Ank KI/KI mice . FGF23 has been associated with a number of human diseases, including X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets (ADHR), chronic kidney disease (CKD), familial tumoral calcinosis, McCune-Albright syndrome, and fibrous dysplasia of bone [25–29]. Unexpectedly, we did not detect significant differences in FGF23 protein expression in femoral bones or of the active form of FGF23 in serum from Ank +/+ and Ank KI/KI mice. We also did not observe significant pathological changes in renal morphology or in abnormal mRNA expression of FGF23-target genes in Ank KI/KI kidneys. Although the mechanisms that would explain the discrepancy between Fgf23 mRNA and FGF23 protein levels are yet unknown, our data suggests that increased Fgf23 transcripts are unlikely the primary factor contributing to the skeletal phenotype in CMD.
Normalization of serum Pi levels in Ank KI/KI mice as they age suggests that a feedback mechanism may be involved to correct the decreased Pi levels as Ank KI/KI mice age . We therefore examined levels of FGF23, PTH and 1,25-(OH)2D3 which are regulators known to control Pi homeostasis [30, 31]. The active form 1,25-(OH)2D3 results from formation of cholecalciferol in the skin by photolysis of 7-dehydrocholesterol under sunlight exposure followed by hydroxylation of cholecalciferol to 25-hydroxy vitamin D (25OHD) in the liver. 25OHD is further hydroxylated in the kidney to form the active form 1,25-(OH)2D3. Although commercial kits are available to measure 1,25-(OH)2D3, the vitamin D status is best determined by 25OHD levels [32, 33]. This is because 25OHD has a half-life of approximately 3 weeks whereas 1,25(OH)2D3 has a half-life of only 4–6 h. 25OHD is unregulated and can reflect substrate availability. On the other hand, 1,25-(OH)2D3 is highly regulated and therefore provides limited information about the vitamin D status. In both, CMD mice and patients with CMD, we found normal intact FGF23 and PTH levels. 25OHD was transiently lower in Ank KI/KI mice at the age of 10 weeks but became comparable to Ank +/+ mice as they aged to 16 weeks. Four out of seven CMD patients showed vitamin D insufficiency or deficiency. Lower vitamin D levels may be associated with insufficient nutritional uptake, reduced sun exposure or the status of vitamin D binding protein (DBP). A recent study suggests that a specific type of nucleotide polymorphisms in Gc, the gene encoding DBP, is associated with the highest 25OHD concentration compared to other lower affinity Gc variants in West African children . Further studies will be needed to investigate mechanisms leading to decreased vitamin D levels in CMD, such as whether DBP status is affected by CMD ANKH mutations. Due to the limited number of CMD cases in this study no conclusion can be drawn based on biochemical analyses.
There are several limitations to this study. One limitation is that we have samples from only seven CMD patients of different gender and age because CMD is a very rare disorder. Secondly, it has been challenging to recruit healthy age and sex matched subjects as controls for the individual assays. We thus compared our data to well-accepted normal ranges of FGF23, PTH and 25OHD. Lastly, the mechanisms of increased cleavage of FGF23 and transiently decreased vitamin D in Ank KI/KI mice are still unknown. Nonetheless, this project is significant as we show that Pi metabolism is not significantly affected and thus is unlikely a major contributor to CMD. A tight balance between Pi and PPi is important for regulation of skeletal modeling and remodeling. CMD mutant ANK has been reported to reduce PPi transporting activity . Although we found that Pi metabolism or Pi levels are not severely altered in CMD mice or patients, adjusting the Pi/PPi ratio might ameliorate skeletal abnormalities of CMD. Clinically, patients can reduce serum Pi levels by avoiding foods that are high in Pi or by Pi binders, such as aluminum salts, calcium carbonate, calcium acetate and lanthanum carbonate. Future studies will focus on whether a low Pi diet in Ank KI/KI mice is beneficial for correcting a possibly altered Pi/PPi ratio in CMD, which may be caused by decreased PPi.
Our data indicate that the bone-kidney axis of FGF23 is not a primary contributor to the pathology of CMD. Levels of circulating PTH and active form of FGF23 are within the normal range in Ank KI/KI mice and CMD patients. High Pi diet does not appear to correct the bone phenotype of CMD.
progressive ankylosis gene
fibroblast growth factor 23
We are indebted to Drs. Quan Yuan and Beate Lanske for helpful discussions.
The project was supported by White Coat Gala Fund at UConn Health to IPC and R01 DE019458 (NIDCR) to EJR. This study was also supported by the National Institutes of Health through the National Center for Research Resources grant M01RR006192 to the Clinical Research Center at UConn Health.
Availability of data and materials
All data generated in this study are included in the published article.
YL and ED performed gene expression analyses, immunohistochemistry, mouse breeding and mouse bone collection. EJR recruited CMD patients, contributed to the study design, data discussion and the manuscript. IPC performed ELISA assays, wrote the manuscript, contributed to the study design and data interpretation. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
Research involving human subjects has been approved by the University of Connecticut Health Institutional Review Board (IRB number: 03-008-1) and written informed consent has been obtained from all participants. The animal protocol (100782–1116) was approved by the Institutional Animal Care and Use Committee (IACUC) of University of Connecticut Health and all work was performed in an AAALAC accredited facility.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Jackson WP, et al. Metaphyseal dysplasia, epiphyseal dysplasia, diaphyseal dysplasia, and related conditions. I. Familial metaphyseal dysplasia and craniometaphyseal dysplasia; their relation to leontiasis ossea and osteopetrosis; disorders of bone remodeling. AMA Arch Intern Med. 1954;94(6):871–85.View ArticlePubMedGoogle Scholar
- Cheung VG, Boechat MI, Barrett CT. Bilateral choanal narrowing as a presentation of craniometaphyseal dysplasia. J Perinatol. 1997;17(3):241–3.PubMedGoogle Scholar
- Richards A, et al. Craniometaphyseal and craniodiaphyseal dysplasia, head and neck manifestations and management. J Laryngol Otol. 1996;110(4):328–38.View ArticlePubMedGoogle Scholar
- Chen IP, et al. Introduction of a Phe377del mutation in ANK creates a mouse model for craniometaphyseal dysplasia. J Bone Miner Res. 2009;24(7):1206–15.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen IP, et al. A Phe377del mutation in ANK leads to impaired osteoblastogenesis and osteoclastogenesis in a mouse model for craniometaphyseal dysplasia (CMD). Hum Mol Genet. 2011;20(5):948–61.View ArticlePubMedGoogle Scholar
- Shimada T, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19(3):429–35.View ArticlePubMedGoogle Scholar
- Urakawa I, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444(7120):770–4.View ArticlePubMedGoogle Scholar
- Bai X, et al. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology. 2004;145(11):5269–79.View ArticlePubMedGoogle Scholar
- Shimada T, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113(4):561–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Reichenberger E, et al. Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet. 2001;68(6):1321–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Nurnberg P, et al. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet. 2001;28(1):37–41.PubMedGoogle Scholar
- Gurley KA, et al. Mineral formation in joints caused by complete or joint-specific loss of ANK function. J Bone Miner Res. 2006;21(8):1238–47.View ArticlePubMedGoogle Scholar
- Gurley KA, Reimer RJ, Kingsley DM. Biochemical and genetic analysis of ANK in arthritis and bone disease. Am J Hum Genet. 2006;79(6):1017–29.View ArticlePubMedPubMed CentralGoogle Scholar
- Kawata T, et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol. 2007;18(10):2683–8.View ArticlePubMedGoogle Scholar
- Liu S, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006;17(5):1305–15.View ArticlePubMedGoogle Scholar
- Kolek OI, et al. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol. 2005;289(6):G1036–42.View ArticlePubMedGoogle Scholar
- Frishberg Y, et al. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res. 2007;22(2):235–42.View ArticlePubMedGoogle Scholar
- Zhang R, et al. Unique roles of phosphorus in endochondral bone formation and osteocyte maturation. J Bone Miner Res. 2011;26(5):1047–56.View ArticlePubMedGoogle Scholar
- Dutra EH, et al. Two novel large ANKH deletion mutations in sporadic cases with craniometaphyseal dysplasia. Clinical Genetics. 2012;81(1):93–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Mintz S, Velez I. Craniometaphyseal dysplasia associated with obstructive sleep apnoea syndrome. Dentomaxillofacial Radiol. 2004;33(4):262–6.View ArticleGoogle Scholar
- Yamamoto T, et al. Bone marrow-derived osteoclast-like cells from a patient with craniometaphyseal dysplasia lack expression of osteoclast-reactive vacuolar proton pump. J Clin Investig. 1993;91(1):362–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Morava E, et al. Autosomal recessive mental retardation, deafness, ankylosis, and mild hypophosphatemia associated with a novel ANKH mutation in a consanguineous family. J Clin Endocrinol Metab. 2011;96(1):E189–98.View ArticlePubMedGoogle Scholar
- Kanatani M, et al. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. J Cell Physiol. 2003;196(1):180–9.View ArticlePubMedGoogle Scholar
- Hayashibara T, et al. Regulation of Osteoclast Differentiation and Function by Phosphate: Potential Role of Osteoclasts in the Skeletal Abnormalities in Hypophosphatemic Conditions. J Bone Miner Res. 2007;22(11):1743–51.View ArticlePubMedGoogle Scholar
- A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet. 1995;11(2):130–6.
- Consortium A. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26(3):345–8.View ArticleGoogle Scholar
- Larsson T, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64(6):2272–9.View ArticlePubMedGoogle Scholar
- Larsson T, et al. A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab. 2005;90(4):2424–7.View ArticlePubMedGoogle Scholar
- Riminucci M, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003;112(5):683–92.View ArticlePubMedPubMed CentralGoogle Scholar
- Potts JT. Parathyroid hormone: past and present. J Endocrinol. 2005;187(3):311–25.View ArticlePubMedGoogle Scholar
- Torres PA, De Brauwere DP. Three feedback loops precisely regulating serum phosphate concentration. Kidney Int. 2011;80(5):443–5.View ArticlePubMedGoogle Scholar
- Holick MF. The use and interpretation of assays for vitamin D and its metabolites. J Nutr. 1990;120 Suppl 11:1464–9.PubMedGoogle Scholar
- Iqbal SJ. Vitamin D metabolism and the clinical aspects of measuring metabolites. Ann Clin Biochem. 1994;31(Pt 2):109–24.View ArticlePubMedGoogle Scholar
- Braithwaite VS, et al. Vitamin D binding protein genotype is associated with plasma 25OHD concentration in West African children. Bone. 2015;74:166–70.View ArticlePubMedPubMed CentralGoogle Scholar